Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CORT

Corcept Therapeutics Inc

Sep 12 • 04:00PM ET

72.87

-1.46 -1.96 %

Healthcare • Biotechnology • USA • NASD

Peers: NBIX SRPT TGTX MDGL ARDX ANAB VKTX AKBA LGND PSTV

| Held by: IJR VTI VB VBK VXF SPSM IJT XSMO IWP FBT

Scroll to Statements

Index	-	P/E	64.85	EPS (ttm)	1.12	Insider Own	11.48%	Shs Outstand	105.29M	Perf Week	5.06%
Market Cap	7.68B	Forward P/E	33.27	EPS next Y	2.19	Insider Trans	-6.34%	Shs Float	93.28M	Perf Month	0.10%
Enterprise Value	7.34B	PEG	1.01	EPS next Q	0.17	Inst Own	75.41%	Short Float	11.67%	Perf Quarter	2.37%
Income	131.98M	P/S	10.72	EPS this Y	-12.20%	Inst Trans	-5.42%	Short Ratio	10.58	Perf Half Y	32.85%
Sales	716.08M	P/B	12.07	EPS next Y	102.78%	ROA	17.41%	Short Interest	10.88M	Perf YTD	44.61%
Book/sh	6.04	P/C	22.44	EPS next 5Y	64.45%	ROE	21.42%	52W High	117.33 -37.89%	Perf Year	108.02%
Cash/sh	3.25	P/FCF	42.59	EPS past 3/5Y	11.29% 9.89%	ROIC	20.58%	52W Low	35.45 105.56%	Perf 3Y	176.76%
Dividend Est.	-	EV/EBITDA	70.71	Sales past 3/5Y	22.64% 17.11%	Gross Margin	98.37%	Volatility	4.16% 2.77%	Perf 5Y	264.71%
Dividend TTM	-	EV/Sales	10.25	EPS Y/Y TTM	4.48%	Oper. Margin	14.24%	ATR (14)	2.29	Perf 10Y	1384.11%
Dividend Ex-Date	-	Quick Ratio	2.98	Sales Y/Y TTM	25.71%	Profit Margin	18.43%	RSI (14)	56.89	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.06	EPS Q/Q	-9.00%	SMA20	2.92%	Beta	0.44	Target Price	135.25
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	18.70%	SMA50	3.11%	Rel Volume	0.65	Prev Close	74.33
Employees	500	LT Debt/Eq	0.01	Earnings	Jul 31 AMC	SMA200	9.76%	Avg Volume	1.03M	Price	72.87
IPO	Apr 14, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	54.67% -2.49%	Trades		Volume	664,013	Change	-1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-06-23	Upgrade	Truist	Hold → Buy	$29 → $38
Apr-11-23	Initiated	SVB Securities	Market Perform	$25
Apr-04-23	Initiated	Piper Sandler	Overweight	$27
Feb-15-23	Downgrade	Jefferies	Buy → Hold	$35 → $22
Aug-01-22	Downgrade	Truist	Buy → Hold	$30
Jul-27-22	Upgrade	Jefferies	Hold → Buy	$21 → $35
Jun-27-22	Resumed	Canaccord Genuity	Buy	$30 → $34
Feb-02-22	Initiated	Canaccord Genuity	Buy	$30
Jan-28-22	Initiated	Truist	Buy	$30
Aug-05-20	Downgrade	Jefferies	Buy → Hold	$16
Sep-24-19	Initiated	Jefferies	Buy	$20
Sep-06-19	Initiated	H.C. Wainwright	Buy	$18
Feb-04-19	Downgrade	B. Riley FBR	Buy → Neutral	$22 → $12
Aug-10-18	Reiterated	Stifel	Hold	$20 → $11
May-31-18	Downgrade	Stifel	Buy → Hold	$20
Mar-09-18	Initiated	B. Riley FBR, Inc.	Buy	$30
Aug-31-17	Initiated	Stifel	Buy	$20
Feb-02-17	Initiated	Ladenburg Thalmann	Buy	$14
Apr-21-15	Initiated	FBR Capital	Outperform	$12
Jan-13-14	Downgrade	Stifel	Buy → Hold

Show Previous Ratings

Sep-11-25 11:57AM	FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer (Zacks)
03:31AM	Corcept's (CORT) Multibagger Momentum Builds on Relacorilant and Expanding Commercial Footprint (Insider Monkey)
Sep-10-25 08:00AM	FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Sep-02-25 09:58AM	Can Korlym Drive Corcept's Growth Through the Rest of 2025? (Zacks)
Aug-25-25 02:03PM	Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock? (Zacks)
11:57PM	Loading…
Aug-22-25 11:57PM	Canaccord Genuity Maintains a Buy on Corcept Therapeutics (CORT), Retains a $137 PT (Insider Monkey)
Aug-13-25 12:25AM	5 Must-Read Analyst Questions From Corcept's Q2 Earnings Call (StockStory)
12:00AM	CORT Q2 Deep Dive: Product Supply Constraints and Pipeline Progress Reshape Outlook (StockStory)
Aug-01-25 12:04PM	CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down (Zacks)
Jul-31-25 05:35PM	Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates (Zacks)
05:27PM	Corcept (NASDAQ:CORT) Misses Q2 Sales Targets (StockStory)
04:36PM	Corcept: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update (Business Wire)
Jul-29-25 11:05PM	What To Expect From Corcept's (CORT) Q2 Earnings (StockStory)
Jul-28-25 02:07AM	H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT) (Insider Monkey)
09:58AM	Loading…
Jul-27-25 09:58AM	Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk (Insider Monkey)
Jul-24-25 11:48PM	Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant (Insider Monkey)
04:05PM	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call (Business Wire)
Jul-23-25 11:00AM	Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects (Insider Monkey)
Jul-17-25 07:10AM	Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last? (Zacks)
12:08AM	3 Reasons CORT is Risky and 1 Stock to Buy Instead (StockStory)
Jul-15-25 10:17AM	Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer (Zacks)
Jul-14-25 08:00AM	Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Jul-06-25 04:15AM	Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial (Insider Monkey)
Jul-04-25 01:48AM	Corcept Therapeutics' Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients (Insider Monkey)
Jun-30-25 06:20AM	Should Invesco S&P SmallCap Momentum ETF (XSMO) Be on Your Investing Radar? (Zacks)
Jun-27-25 08:56AM	Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? (Zacks)
Jun-26-25 05:52PM	5 Insightful Analyst Questions From Corcept's Q1 Earnings Call (StockStory)
Jun-24-25 03:09PM	Corcept ALS Drug Shows Significant Survival Benefit Despite Missed Primary Endpoint (Insider Monkey)
Jun-23-25 04:30PM	Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care (Business Wire)
06:20AM	Loading…
Jun-16-25 06:20AM	Should JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) Be on Your Investing Radar? (Zacks)
Jun-11-25 06:20AM	Is Invesco S&P SmallCap Quality ETF (XSHQ) a Strong ETF Right Now? (Zacks)
Jun-06-25 06:20AM	Should Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF (GSSC) Be on Your Investing Radar? (Zacks)
Jun-05-25 11:20AM	Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study (Benzinga)
06:20AM	Should Invesco S&P SmallCap Quality ETF (XSHQ) Be on Your Investing Radar? (Zacks)
06:00AM	Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting (Business Wire)
Jun-04-25 11:30AM	Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-03-25 02:59AM	Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday (Insider Monkey)
Jun-02-25 11:15AM	Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer (Business Wire) -7.58%
May-29-25 06:11AM	New Strong Sell Stocks for May 29th (Zacks)
May-21-25 11:31PM	Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT) (StockStory)
May-19-25 08:04AM	CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed (StockStory)
May-11-25 05:17PM	Why Corcept Therapeutics (CORT) Is Among the Best Performing Healthcare Stocks to Buy Now (Insider Monkey)
May-08-25 12:34AM	1 Small-Cap Stock Worth Your Attention and 2 to Question (StockStory)
May-07-25 10:01AM	Corcept Therapeutics price target lowered to $135 from $150 at Truist (TipRanks)
May-06-25 02:50PM	Q1 2025 Corcept Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
01:12PM	CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall (Zacks)
03:08AM	Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Highlights: Revenue Growth Amid ... (GuruFocus.com)
May-05-25 08:34PM	Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:30PM	Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates (Zacks)
04:26PM	Corcept: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE (Business Wire)
May-04-25 05:25PM	Corcept Therapeutics (CORT): Among Billionaire Jim Simons' RenTech's Small-Cap Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-30-25 08:11PM	Is Corcept Therapeutics Inc. (NASDAQ:CORT) the Best Growth Stock to Buy for the Next 3 Years? (Insider Monkey)
Apr-29-25 11:59AM	Corcept Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
10:01AM	Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
06:20AM	Should iShares Core S&P Small-Cap ETF (IJR) Be on Your Investing Radar? (Zacks)
06:20AM	Should Invesco S&P SmallCap Momentum ETF (XSMO) Be on Your Investing Radar? (Zacks)
Apr-28-25 04:05PM	CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL (Business Wire)
09:01AM	3 Healthcare Stocks That Concern Us (StockStory)
Apr-23-25 06:06PM	BBSC: Lagging Several Small-Cap Core ETFs (Seeking Alpha) +7.10%
12:55PM	Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
11:30AM	CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 (Business Wire)
Apr-22-25 05:23PM	Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss (Seeking Alpha)
Apr-21-25 08:00AM	Diabetes Care Publishes Results From Prevalence Phase Of Corcepts CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes (Business Wire)
06:20AM	Is Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF (GSSC) a Strong ETF Right Now? (Zacks)
Apr-19-25 05:30AM	ClearBridge Small Cap Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-17-25 06:20AM	Should iShares S&P Small-Cap 600 Growth ETF (IJT) Be on Your Investing Radar? (Zacks)
Apr-15-25 04:00PM	It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder (Seeking Alpha) -7.17%
Apr-10-25 07:00AM	3 Biopharmaceutical Stocks Bucking the Sell-Off (MarketBeat) -7.18%
Apr-07-25 08:00AM	Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer (Business Wire)
Apr-04-25 09:37AM	PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study (Zacks) -6.20%
Apr-03-25 09:32AM	DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up (Zacks) -5.30%
09:08AM	NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program (Zacks)
Apr-02-25 03:00PM	Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More (Zacks) -8.83%
09:55AM	Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect? (Zacks)
09:11AM	APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag (Zacks)
Apr-01-25 01:43PM	Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release (Seeking Alpha) -19.51%
12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks)
10:50AM	CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal (Zacks)
10:28AM	Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? (Zacks)
09:44AM	SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States (Zacks)
09:31AM	AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication (Zacks)
08:50AM	Here's Why Momentum in Corcept (CORT) Should Keep going (Zacks)
07:15AM	Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company (Seeking Alpha)
07:13AM	Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday? (Insider Monkey)
05:39AM	Corcepts Phase III trial of ovarian cancer therapy shows PFS improvement (Clinical Trials Arena)
Mar-31-25 02:48PM	Why Is Corcept (CORT) Stock Soaring Today (StockStory) +109.08%
01:20PM	NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute (Yahoo Finance Video)
11:51AM	Yum Brands, Corcept Therapeutics, Hut 8: Trending tickers (Yahoo Finance Video)
08:18AM	Corcept's ovarian cancer drug cuts disease progression in study, shares jump (Reuters)
08:00AM	Primary Endpoint Met in Corcepts Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Mar-28-25 11:30AM	Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report? (Zacks)
09:45AM	Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
Mar-27-25 12:03PM	ClearBridge Small Cap Fund Q4 2024 Commentary (SeekingAlpha)
09:39AM	PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know (Zacks)
08:46AM	SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug (Zacks)
Mar-26-25 05:41PM	3 Reasons to Sell CORT and 1 Stock to Buy Instead (StockStory)
Mar-21-25 09:40AM	Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-19-25 09:03AM	3 Growth Stocks in Hot Water (StockStory)

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Swisher Daniel N JR	Director	Sep 10 '25	Option Exercise	14.08	2,200	30,976	2,200	Sep 11 08:38 PM
Swisher Daniel N JR	Director	Sep 10 '25	Sale	72.45	2,200	159,390	0	Sep 11 08:38 PM
Swisher Daniel N JR	Director	Sep 10 '25	Proposed Sale	72.45	2,200	159,390		Sep 10 09:50 AM
Cannon Gillian	Director	Sep 04 '25	Option Exercise	22.99	11,000	252,890	11,000	Sep 08 08:20 PM
Guyer William	Chief Development Officer	Sep 02 '25	Option Exercise	21.65	20,000	433,000	25,487	Sep 04 07:59 PM
Guyer William	Chief Development Officer	Sep 02 '25	Sale	70.49	20,000	1,409,848	5,487	Sep 04 07:59 PM
Lyon Joseph Douglas	See Remarks	Sep 02 '25	Option Exercise	13.56	5,000	67,800	15,066	Sep 04 07:56 PM
Lyon Joseph Douglas	See Remarks	Sep 02 '25	Sale	70.25	5,000	351,247	10,066	Sep 04 07:56 PM
Maduck Sean	See Remarks	Sep 02 '25	Option Exercise	5.05	20,000	101,000	27,681	Sep 04 07:54 PM
Maduck Sean	See Remarks	Sep 02 '25	Sale	70.49	20,000	1,409,828	7,681	Sep 04 07:54 PM
BELANOFF JOSEPH K	Chief Executive Officer	Sep 02 '25	Sale	70.53	40,000	2,821,033	2,821,370	Sep 04 07:54 PM
Guyer William	Officer	Sep 02 '25	Proposed Sale	69.72	20,000	1,394,400		Sep 02 04:31 PM
Maduck Sean	Officer	Sep 02 '25	Proposed Sale	69.72	20,000	1,394,400		Sep 02 04:23 PM
Lyon Joseph Douglas	Officer	Sep 02 '25	Proposed Sale	69.72	5,000	348,600		Sep 02 04:16 PM
BELANOFF JOSEPH K	Officer	Sep 02 '25	Proposed Sale	69.72	40,000	2,788,800		Sep 02 04:09 PM
Robb Gary Charles	Chief Business Officer	Aug 22 '25	Option Exercise	3.88	5,000	19,400	18,364	Aug 26 06:56 PM
Robb Gary Charles	Chief Business Officer	Aug 22 '25	Sale	71.27	2,326	165,774	16,038	Aug 26 06:56 PM
Robb Gary Charles	Officer	Aug 22 '25	Proposed Sale	71.27	2,326	165,774		Aug 22 10:58 AM
Swisher Daniel N JR	Director	Aug 11 '25	Option Exercise	14.08	2,200	30,976	2,200	Aug 12 07:22 PM
Swisher Daniel N JR	Director	Aug 11 '25	Sale	72.30	2,200	159,060	0	Aug 12 07:22 PM
Guyer William	Chief Development Officer	Aug 08 '25	Option Exercise	21.65	35,007	757,902	40,494	Aug 12 07:19 PM
Guyer William	Chief Development Officer	Aug 08 '25	Sale	71.77	35,007	2,512,452	5,487	Aug 12 07:19 PM
Swisher Daniel N JR	Director	Aug 11 '25	Proposed Sale	72.30	2,200	159,060		Aug 11 10:20 AM
Guyer William	Chief Development Officer	Aug 05 '25	Option Exercise	21.65	14	303	5,501	Aug 07 07:17 PM
Guyer William	Chief Development Officer	Aug 05 '25	Sale	71.77	14	1,005	5,487	Aug 07 07:17 PM
Maduck Sean	See Remarks	Aug 01 '25	Option Exercise	5.05	35,007	176,785	42,688	Aug 05 06:51 PM
Maduck Sean	See Remarks	Aug 01 '25	Sale	67.79	35,007	2,373,237	7,681	Aug 05 06:51 PM
BELANOFF JOSEPH K	Chief Executive Officer	Aug 01 '25	Sale	68.53	40,000	2,741,207	2,861,370	Aug 05 06:51 PM
Lyon Joseph Douglas	See Remarks	Aug 01 '25	Option Exercise	13.56	5,823	78,960	15,889	Aug 05 06:47 PM
Lyon Joseph Douglas	See Remarks	Aug 01 '25	Sale	67.51	5,823	393,128	10,066	Aug 05 06:47 PM
Guyer William	Officer	Aug 05 '25	Proposed Sale	71.77	20,000	1,435,400		Aug 05 01:05 PM
Lyon Joseph Douglas	Officer	Aug 01 '25	Proposed Sale	67.17	5,000	335,850		Aug 01 11:25 AM
Maduck Sean	Officer	Aug 01 '25	Proposed Sale	67.15	20,000	1,343,000		Aug 01 11:11 AM
BELANOFF JOSEPH K	Officer	Aug 01 '25	Proposed Sale	67.17	615	41,310		Aug 01 11:00 AM
Maduck Sean	See Remarks	Jul 17 '25	Option Exercise	5.05	4,315	21,791	22,020	Jul 21 07:14 PM
Maduck Sean	See Remarks	Jul 18 '25	Option Exercise	5.05	473	2,389	18,178	Jul 21 07:14 PM
Maduck Sean	See Remarks	Jul 17 '25	Sale	73.48	4,315	317,054	17,705	Jul 21 07:14 PM
Maduck Sean	See Remarks	Jul 18 '25	Sale	73.44	473	34,737	17,705	Jul 21 07:14 PM
BELANOFF JOSEPH K	Chief Executive Officer	Jul 17 '25	Sale	73.69	615	45,318	2,901,370	Jul 21 07:11 PM
Lyon Joseph Douglas	See Remarks	Jul 17 '25	Option Exercise	13.56	3,877	52,572	13,943	Jul 21 07:10 PM
Lyon Joseph Douglas	See Remarks	Jul 18 '25	Option Exercise	13.56	200	2,712	10,266	Jul 21 07:10 PM
Lyon Joseph Douglas	See Remarks	Jul 17 '25	Sale	73.48	3,877	284,864	10,066	Jul 21 07:10 PM
Lyon Joseph Douglas	See Remarks	Jul 18 '25	Sale	73.40	200	14,680	10,066	Jul 21 07:10 PM
Guyer William	Chief Development Officer	Jul 17 '25	Option Exercise	21.65	4,379	94,805	9,866	Jul 21 07:10 PM
Guyer William	Chief Development Officer	Jul 18 '25	Option Exercise	21.65	500	10,825	5,987	Jul 21 07:10 PM
Guyer William	Chief Development Officer	Jul 17 '25	Sale	73.48	4,379	321,774	5,487	Jul 21 07:10 PM
Guyer William	Chief Development Officer	Jul 18 '25	Sale	73.44	500	36,721	5,487	Jul 21 07:10 PM
BELANOFF JOSEPH K	Officer	Jul 17 '25	Proposed Sale	72.85	40,000	2,914,000		Jul 17 04:00 PM
Swisher Daniel N JR	Director	Jul 10 '25	Option Exercise	14.08	2,200	30,976	2,200	Jul 14 04:36 PM
Swisher Daniel N JR	Director	Jul 10 '25	Sale	71.08	2,200	156,376	0	Jul 14 04:36 PM
Swisher Daniel N JR	Director	Jul 10 '25	Proposed Sale	71.08	2,200	156,376		Jul 10 12:21 PM
Guyer William	Chief Development Officer	Jul 01 '25	Option Exercise	21.65	100	2,165	5,587	Jul 03 08:39 PM
Guyer William	Chief Development Officer	Jul 01 '25	Sale	73.50	100	7,350	5,487	Jul 03 08:39 PM
Lyon Joseph Douglas	See Remarks	Jul 01 '25	Option Exercise	13.56	100	1,356	10,166	Jul 03 08:36 PM
Lyon Joseph Douglas	See Remarks	Jul 01 '25	Sale	73.50	100	7,350	10,066	Jul 03 08:36 PM
Maduck Sean	See Remarks	Jul 01 '25	Option Exercise	5.05	205	1,035	17,910	Jul 03 08:35 PM
Maduck Sean	See Remarks	Jul 01 '25	Sale	73.45	205	15,058	17,705	Jul 03 08:35 PM
Maduck Sean	Officer	Jul 01 '25	Proposed Sale	73.40	20,000	1,468,000		Jul 01 02:09 PM
Lyon Joseph Douglas	Officer	Jul 01 '25	Proposed Sale	73.40	5,000	367,000		Jul 01 02:01 PM
Guyer William	Officer	Jul 01 '25	Proposed Sale	73.40	20,000	1,468,000		Jul 01 01:52 PM
Robb Gary Charles	Chief Business Officer	Jun 16 '25	Sale	70.77	3,185	225,402	13,364	Jun 18 06:26 PM
Robb Gary Charles	Officer	Jun 16 '25	Proposed Sale	70.77	3,185	225,402		Jun 16 04:58 PM
Swisher Daniel N JR	Director	Jun 10 '25	Option Exercise	14.08	2,200	30,976	2,200	Jun 12 08:42 PM
Swisher Daniel N JR	Director	Jun 10 '25	Sale	70.61	2,200	155,342	0	Jun 12 08:42 PM
Guyer William	Chief Development Officer	Jun 10 '25	Option Exercise	21.65	20,000	433,000	25,487	Jun 12 08:41 PM
Guyer William	Chief Development Officer	Jun 10 '25	Sale	72.42	20,000	1,448,475	5,487	Jun 12 08:41 PM
Swisher Daniel N JR	Director	Jun 10 '25	Proposed Sale	70.61	2,200	155,342		Jun 10 11:03 AM
BELANOFF JOSEPH K	Chief Executive Officer	Jun 02 '25	Sale	82.86	40,000	3,314,310	2,901,985	Jun 04 08:41 PM
Lyon Joseph Douglas	See Remarks	Jun 02 '25	Option Exercise	13.56	5,000	67,800	14,009	Jun 04 08:34 PM
Lyon Joseph Douglas	See Remarks	Jun 02 '25	Sale	78.04	5,000	390,218	9,009	Jun 04 08:34 PM
Maduck Sean	See Remarks	Jun 02 '25	Sale	79.08	20,000	1,581,686	17,705	Jun 04 08:33 PM
Guyer William	Officer	Jun 03 '25	Proposed Sale	71.68	20,000	1,433,600		Jun 03 03:59 PM
Maduck Sean	See Remarks	May 29 '25	Option Exercise	3.88	10,000	38,800	25,929	Jun 02 08:57 PM
BELANOFF JOSEPH K	Officer	Jun 02 '25	Proposed Sale	77.56	40,000	3,102,400		Jun 02 02:31 PM
Maduck Sean	Officer	Jun 02 '25	Proposed Sale	77.56	20,000	1,551,200		Jun 02 02:25 PM
Lyon Joseph Douglas	Officer	Jun 02 '25	Proposed Sale	77.56	5,000	387,800		Jun 02 01:59 PM
Robb Gary Charles	Chief Business Officer	May 20 '25	Sale	75.85	2,279	172,862	16,586	May 22 04:48 PM
Guyer William	Chief Development Officer	May 16 '25	Option Exercise	21.65	32,262	698,472	37,749	May 20 07:35 PM
Guyer William	Chief Development Officer	May 16 '25	Sale	74.17	32,262	2,393,014	5,487	May 20 07:35 PM
MAHONEY DAVID L	Director	May 16 '25	Option Exercise	6.55	30,000	196,500	30,000	May 20 07:13 PM
MAHONEY DAVID L	Director	May 16 '25	Sale	74.23	27,352	2,030,452	0	May 20 07:13 PM
Robb Gary Charles	Officer	May 20 '25	Proposed Sale	75.85	2,279	172,862		May 20 02:29 PM
MAHONEY DAVID L	Director	May 16 '25	Proposed Sale	74.23	27,352	2,030,454		May 16 02:32 PM
Guyer William	Officer	May 16 '25	Proposed Sale	74.17	20,000	1,483,400		May 16 01:40 PM
Swisher Daniel N JR	Director	May 12 '25	Option Exercise	12.48	2,200	27,466	2,200	May 14 05:51 PM
Swisher Daniel N JR	Director	May 12 '25	Sale	72.06	2,200	158,526	0	May 14 05:51 PM
Swisher Daniel N JR	Director	May 12 '25	Proposed Sale	71.55	400	28,620		May 12 03:54 PM
Swisher Daniel N JR	Director	May 12 '25	Proposed Sale	72.17	1,800	129,906		May 12 10:40 AM
Guyer William	Chief Development Officer	May 06 '25	Option Exercise	21.65	7,060	152,849	12,547	May 08 08:20 PM
Guyer William	Chief Development Officer	May 06 '25	Sale	74.31	7,060	524,653	5,487	May 08 08:20 PM
Maduck Sean	See Remarks	May 02 '25	Option Exercise	5.05	26,554	134,098	112,176	May 05 08:33 PM
Maduck Sean	See Remarks	May 01 '25	Option Exercise	5.05	12,856	64,923	98,478	May 05 08:33 PM
Maduck Sean	See Remarks	May 02 '25	Sale	72.23	26,554	1,917,951	85,622	May 05 08:33 PM
Maduck Sean	See Remarks	May 01 '25	Sale	71.94	12,856	924,818	85,622	May 05 08:33 PM
BELANOFF JOSEPH K	Chief Executive Officer	May 02 '25	Sale	72.90	40,000	2,915,922	2,941,985	May 05 08:28 PM
Lyon Joseph Douglas	See Remarks	May 01 '25	Option Exercise	13.56	9,350	126,786	18,359	May 05 08:26 PM
Lyon Joseph Douglas	See Remarks	May 01 '25	Sale	71.96	9,350	672,781	9,009	May 05 08:26 PM
BELANOFF JOSEPH K	Officer	May 02 '25	Proposed Sale	71.48	350	25,018		May 02 04:01 PM
Maduck Sean	Officer	May 02 '25	Proposed Sale	71.48	20,000	1,429,600		May 02 03:52 PM
Lyon Joseph Douglas	Officer	May 01 '25	Proposed Sale	71.88	5,000	359,400		May 01 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CORT

Corcept Therapeutics Inc

Upgrade your FINVIZ experience